Swedish Orphan Biovitrum Overview
- Year Founded
-
1939
- Status
-
Public
- Employees
-
2,207
- Stock Symbol
-
SOBI
- Investments
-
12
- Share Price
-
$47.25
- (As of Friday Closing)
Swedish Orphan Biovitrum General Information
Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Contact Information
Website
www.sobi.comCorporate Office
- Norra Stationsgatan 93A
- Stockholm
- Sweden
Corporate Office
- Norra Stationsgatan 93A
- Stockholm
- Sweden
Swedish Orphan Biovitrum Stock Performance
As of 13-Nov-2026, Swedish Orphan Biovitrum’s stock price is $47.25. Its current market cap is $16.4B with 348M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $47.25 | $48.86 | $33.78 - $51.24 | $16.4B | 348M | 335K | $2.04 |
Swedish Orphan Biovitrum Financials Summary
As of 30-Sep-2026, Swedish Orphan Biovitrum has a trailing 12-month revenue of $3.4B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 16,952,186 | 13,853,612 | 11,474,883 | 11,113,564 |
| Revenue | 3,402,473 | 2,874,179 | 2,460,963 | 2,081,362 |
| EBITDA | 1,348,602 | 437,773 | 882,948 | 678,044 |
| Net Income | 705,270 | 48,653 | 367,343 | 226,642 |
| Total Assets | 8,550,784 | 7,328,253 | 6,837,721 | 7,407,189 |
| Total Debt | 1,616,021 | 1,249,196 | 1,516,744 | 2,049,842 |
Swedish Orphan Biovitrum Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Swedish Orphan Biovitrum Comparisons
Industry
Financing
Details
Swedish Orphan Biovitrum Competitors (36)
One of Swedish Orphan Biovitrum’s 36 competitors is Novo Nordisk, a Corporation company based in Bagsvaerd, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
Swedish Orphan Biovitrum Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Swedish Orphan Biovitrum Patents
Swedish Orphan Biovitrum Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4568694-A1 | Anakinra for the treatment of post acute covid syndrome | Pending | 12-Aug-2022 | ||
| US-20260053893-A1 | Anakinra for the treatment of post acute covid syndrome | Pending | 12-Aug-2022 | ||
| WO-2024033530-A1 | Anakinra for the treatment of post acute covid syndrome | Inactive | 12-Aug-2022 | ||
| EP-4121091-A1 | New therapeutic use of anakinra for covid-19 | Inactive | 16-Mar-2020 | ||
| US-20230114594-A1 | New therapeutic use of anakinra for covid-19 | Inactive | 16-Mar-2020 | A61K38/2006 |
Swedish Orphan Biovitrum Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Swedish Orphan Biovitrum Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Swedish Orphan Biovitrum Investments & Acquisitions (12)
Swedish Orphan Biovitrum’s most recent deal was a Corporate Asset Purchase with Innate Pharma (Global Rights of CTCL Drug Lacutamab) for . The deal was made on 01-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Innate Pharma (Global Rights of CTCL Drug Lacutamab) | 01-Aug-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Arthrosi Therapeutics | 09-Feb-2026 | Merger/Acquisition | Drug Discovery | ||
| Pint Pharma | 16-Sep-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Sobi-Handok | 17-Apr-2024 | Joint Venture | Pharmaceuticals | ||
| CTI BioPharma | 10-May-2023 | Merger/Acquisition | Drug Discovery |
Swedish Orphan Biovitrum ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Swedish Orphan Biovitrum Exits (1)
Swedish Orphan Biovitrum’s most recent exit was on 28-Jul-2020 from Selecta Biosciences. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Selecta Biosciences | 28-Jul-2020 | Completed |
|
Swedish Orphan Biovitrum Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cleopatra Acquisition | Seattle, WA | 2023 | |
| Arthrosi Therapeutics | San Diego, CA | 2018 | |
| Swedish Orphan Biovitrum (Belgium) | Zaventem, Belgium | 2013 | |
| Biovitrum | Stockholm, Sweden | 2001 | |
| Arexis | Gothenburg, Sweden | 1999 |
Swedish Orphan Biovitrum FAQs
-
When was Swedish Orphan Biovitrum founded?
Swedish Orphan Biovitrum was founded in 1939.
-
Where is Swedish Orphan Biovitrum headquartered?
Swedish Orphan Biovitrum is headquartered in Stockholm, Sweden.
-
What is the size of Swedish Orphan Biovitrum?
Swedish Orphan Biovitrum has 2,207 total employees.
-
What industry is Swedish Orphan Biovitrum in?
Swedish Orphan Biovitrum’s primary industry is Biotechnology.
-
Is Swedish Orphan Biovitrum a private or public company?
Swedish Orphan Biovitrum is a Public company.
-
What is Swedish Orphan Biovitrum’s stock symbol?
The ticker symbol for Swedish Orphan Biovitrum is SOBI.
-
What is the current stock price of Swedish Orphan Biovitrum?
As of 13-Nov-2026 the stock price of Swedish Orphan Biovitrum is $47.25.
-
What is the current market cap of Swedish Orphan Biovitrum?
The current market capitalization of Swedish Orphan Biovitrum is $16.4B.
-
What is Swedish Orphan Biovitrum’s current revenue?
The trailing twelve month revenue for Swedish Orphan Biovitrum is $3.4B.
-
Who are Swedish Orphan Biovitrum’s competitors?
Novo Nordisk, Gilead, Alnylam Pharmaceuticals, Merck & Co., and Amgen are some of the 36 competitors of Swedish Orphan Biovitrum.
-
What is Swedish Orphan Biovitrum’s annual earnings per share (EPS)?
Swedish Orphan Biovitrum’s EPS for 12 months was $2.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
